Fibrinolytic parameters and insulin resistance in young survivors of myocardial infarction with heterozygous familial hypercholesterolemia

Wiener Klinische Wochenschrift

Volumn 113, Issue 3-4, 2001, Pages 113-118

  Sebestjen M ^a   Zegura B ^a   Guzic Salobir B ^a   Keber, I ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Familial hypercholesterolemia; Fibrinolysis; Insulin resistance; Myocardial infarction

Indexed keywords

FIBRINOGEN; GLUCOSE; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BLOOD ANALYSIS; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL EXAMINATION; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE ASSOCIATION; FAMILIAL HYPERCHOLESTEROLEMIA; FIBRINOLYSIS; HEART INFARCTION; HETEROZYGOSITY; HIGH RISK PATIENT; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; LIPID BLOOD LEVEL; MALE; OBESITY; REGRESSION ANALYSIS; RISK FACTOR; SMOKING; SURVIVAL;

ADULT; AGE FACTORS; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; FIBRINOLYSIS; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INSULIN; INSULIN RESISTANCE; LOGISTIC MODELS; MALE; MIDDLE AGED; MODELS, THEORETICAL; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; RISK FACTORS; SEX FACTORS; TISSUE PLASMINOGEN ACTIVATOR; TRIGLYCERIDES;

EID: 0035864703     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. Cholesterol and coronary heart disease
2. Familial hypercholesterolemia
3. Familial hypercholesterolemia
4. Coronary artery disease in heterozygous familial hypercholesterolemia patients with the same LDL receptor gene mutation
5. Genetic and environmental factors affecting the incidence of coronary artery disease in heterozygous familial hypercholesterolemia
6. Impact of a common mutation of the LDL receptor gene in French-Canadian patients with familial hypercholesterolemia, on means, variances and correlations among traits of lipid metabolism
7. The cardiovascular dymetabolic syndrome
8. Relationship of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene
9. Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris
10. Plasminogen activator inhibitor type I determines plasmin formation in patients with ishemic heart disease
11. Correlations between t-PA and PAI-1 antigen and activity and t-PA/PAI-1 complex in plasma of control subjects and of patients with increased t-PA or PAI-1 levels
12. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes
13. Fibrinolytic activity, clotting factors and long-term incidence of isheamic heart disease in the Northwick Park Heart Study
14. Predictive value of tissue plasminogen activator mass concentration on long-term mortality in patients with coronary artery disease: A 7-year follow-up
15. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction
16. Increased fibrin turnover and high PAI-1 activity as predictors of ishemic events in atherosclerotic patients: A case-control study
17. Von Willebrand factor in plasma: A novel risk factor for recurrent myocardial infarction and death
18. Characteristic affecting fibrinolytic activity and plasma fibrinogen concentration
19. On fibrinolysis in diabetes mellitus
20. Cardiovascular risk continuum: Implications of insulin resistence and diabetes
21. Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis
22. Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics
23. Task force on standardisation of clinical nomenclature. Nomenclature and criteria for diagnosis of ishemic heart disease
24. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
25. Electroimmunoassay
26. Homeostasis model assessment; insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man
27. Evaluation of three methods for plasma fibrinogen determinations
28. Age dependence of tissue plasminogen activator concentration in plasma, as studied by an improved enzyme-linked immunosorbent assay
29. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay
30. Evidence for the occurrence of a fast-acting inhibitor for tissue-type plasminogen activator in human plasma
31. The cellular and molecular mechanisms of diabetic complications
32. Hypertriglyceridemia as a risk factor for coronary heart disease mortality in subject with impaired glucose tolerance or diabetes. Results from 11-year follow-up of the Paris prospective study
33. Is hypertriglyceridemia an independent risk factor for coronary heart disease?
34. Triglycerides: A risk factor for coronary heart disease
35. Plasma high-density lipoprotein concentration and subfraction distribution in relation to plasma triglyceride metabolism
36. Incidence of coronary heart disease and lipoprotein-cholesterol levels: The Framinghan Study
37. Lipids and risk of coronary heart disease: The Framinghan study
38. Endogenous tissue-type plasminogen activator and risk of myocardial infarction
39. Associations of fibrinogen, factor VII and PAI-1 with baseline findings among 10,500 male participants in a prospective study of myocardial infarction. The Prime study
40. Effects of lipids and lipoproteins on thrombosis and rheology
41. Plasminogen activator inhibitor activity and other fibrinolytic variables in patients with coronary artery disease
42. Increased plasma levels of a rapid tissue plasminogen activator in young survivors of myocardial infarction